- ASCs’ vendor problem
- Providence’s physician chief on its ‘holistic’ approach to value-based care
- What the Health? From KFF Health News: A New CDC Nominee, Again
- States Update Guardianship Laws To Keep Children of Immigrants Out of Foster Care
- Anesthesia job market faces ‘major disruption’
- Florida system raises $100M for new ED
- North Carolina system names COO
- Mark Cuban wants to bring drug manufacturing to hospitals’ doorsteps — literally
- UCI Health names chief AI officer
- Nevada hospital names CEO
- Saint Luke’s taps president for 2 hospitals
- Dental community mourns dentist killed in murder-suicide
- Mass General Brigham, CVS deal could raise healthcare spending $40M annually: Report
- Ideal Dental opens 1st Oklahoma practice, expands in 2 more states
- PDS Health eyes the next era of medical-dental integration
- Mark Cuban dives into direct contracting
- HCA executive pay by the numbers
- Iris Telehealth offers behavioral health analytics platform
- HHS names chief economist, regulatory leader to address healthcare affordability
- Loma Linda University Health names new president
- The best ASCs for colonoscopy, endoscopy in the South: US News
- Tennessee moves forward with CON repeal
- Dental schools take action to alleviate workforce shortages: 6 updates
- American Medical Group Association partners with Talkiatry to expand psych access
- Trump nominates CDC director
- ChristianaCare, Cardiovascular Physicians of Delaware to open joint venture ASC
- 5 states regulating AI in mental health
- Centerstone debuts $13M youth behavioral health campus in Missouri
- 3 DSOs making headlines
- Maine restricts noncompetes for rural healthcare workers
- Heartland Dental opens Florida office
- The 10 biggest ASC deals of the last 5 years
- Affordability, transparency: A look at large employers' top healthcare concerns
- 10 dental Medicaid updates to know from Q1
- White House eyes ibogaine research expansion
- New Weight Loss Research Questions Need for GLP-1 Drugs
- Trump Names CDC Director Pick
- SocialRx teams up with FQHC in NYC to prescribe arts and culture for chronically ill patients
- FDA To Review Whether To Allow More Access To Certain Peptides
- Rising Colon Cancer Deaths Hit Younger Adults Without Degrees Hardest
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- The Healthccare Burnout Backlask (pt 4): Why Contract Negotiation Has Become a Core Strategic Skill for Healthcare Administrators
- Over 80% of PCPs concerned about financial stability over next several years
- Industry Voices—DOJ jumps into 340B cases over state law, raising questions about federal plans for the program
- FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER
- Most People Would Take A Blood Test For Alzheimer's, Study Says
- This Sexually Transmitted Infection Linked To Heart Attack, Stroke
- How Playtime at Age 2, Especially with Parents, Shapes Teen Fitness Habits
- New Depression Treatment Matches ECT with Less Memory Loss, Study Says
- Memory Problems? Your Salt Intake Could Make Matters Worse, Study Says
- Ultra-Processed Foods Linked To Fatty Muscles, Potential Knee Arthritis
- Your New Therapist: Chatty, Leaky, and Hardly Human
- Teva scores in appeal as court revives $177M verdict against Lilly in migraine patent spat
- Gen AI chatbots continually struggle with differential diagnoses, Mass General Brigham study finds
- Listen: With Little Federal Regulation, States Are Left To Shape the Rules on AI in Health Care
- Fierce Pharma Asia—Astellas’ stem cell therapy rethink; GSK’s bullish ADC plan; Daiichi’s OTC sale
- BIO comes out swinging with 'Fight of Our Lives' campaign for the industry’s 50th birthday
- The future of medical-dental integration is here
- Texas dentist has license suspended
- Efforts grow to limit corporate dental ownership, protect dentist autonomy: 6 updates
- What’s the deal with insurer mental health parity violations?
- Remarks at the Options Market Structure Roundtable
- Wider care gaps predicted as mental health parity rule faces rollback
- Sheppard Pratt gets $16.5M for behavioral health expansion
- Former Deputy Surgeon General Erica Schwartz, M.D., nominated as CDC director
- Verily Health simplifies medical jargon alphabet soup with AI-powered app in new campaign
- 10 trends in behavioral health usage: Report
- Cattywampus: Statement on the CAT Concept Release
- Providers' advantage on out-of-network billing disputes likely to continue: Capstone
- Butterflies and Condors: Remarks at the Options Market Roundtable
- Viatris, Teva kick off separate recalls over dissolution, raw material issues
- Mental health ED visits at Children’s Hospital Colorado jump 20% in April
- Rising ACA Costs Leave Many Unable To Pay for Coverage
- One Lot of Xanax Recalled Nationwide Over Quality Issue, FDA Says
- Cough Drops From Several Brands Being Recalled, FDA Says
- CDC May Get New Leader as Officials Consider Erica Schwartz
- Statement at the Roundtable on Options
- Opening Remarks at the Options Market Structure Roundtable
- APA launches resource library for trusted digital mental health tools
- E-Bikes And E-Scooters A Growing Menace On City Streets, Study Says
- 'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again
- RFK Jr. kicks off string of congressional hearings to talk White House budget plan
- This Simple Step Could Improve The Benefits From Your Regular Workouts
- New Alzheimer's Drugs Provide No Meaningful Benefit, Major Evidence Review Concludes
- Air Pollution and Weather Tied to Migraines
- Study Says Stress, Weight And Hormones Alter Timing of Puberty in Girls
- Why Walking Remains Unsteady After Partial Spinal Cord Injury
- Roche to launch another Elevidys study after EU rejection of Duchenne gene therapy
- Lilly answers FDA's call for more Foundayo safety info, plotting diabetes filing in parallel
- New Federal Medicaid Rules Require One Month of Work. Some States Demand More.
- As US Birth Rate Falls, Feds’ Response May Make Pregnancy More Dangerous
- Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
- DiMe-led initiative brings together pharma, virtual providers, digital pharmacies to develop blueprint for DTC pharma models
- UPDATED: Heeding RFK Jr.'s call, FDA reclassifies 12 unapproved peptides ahead of advisory committee meeting
- Carrot launches proprietary AI platform for personalized fertility, family care
- UC Health workers plan open-ended, system-wide strike for May 14
- Baylor Scott & White Health Plan to depart individual market, Medicaid this year
- In industry's latest OTC pivot, Daiichi Sankyo lines up $1.5B consumer health unit sale to beverage giant Suntory
- Wildlife Trade Tied To Higher Risk of Diseases Spreading to Humans
- EPA Delays Decisions on 'Forever Chemicals'
- Yes, This is the Worst Pollen Season Ever — Until Next Year
- GoodRx launches 7.2-mg Wegovy dose for self-pay patients at $399 per month
- Providers back bipartisan bill eliminating Medicare chronic care management cost sharing
- Progyny unveils new fertility benefit option for small, mid-size employers
- New Weight Loss Pill, Foundayo, Gets Approval But FDA Seeks More Safety Data
- Seqster launches new data tool to turn clinical sites into 'research-ready data collection points'
- Gilead widens global Yeztugo access agreement, but MSF says supply is 'not nearly enough'
- Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen
- Behavioral health utilization is up with anxiety disorders leading demand, report finds
- Does Your Child Have A Concussion? These Are The Signs, Review Says
- AI Reveals Negative Labels in Medical Records for Sickle Cell Patients
- 'Food-as-Medicine' Improves Life for Heart Failure Patients
- Silent Heart Rhythm Problem Might Triple Risk Of Heart Failure In Seniors
- Blood Test Predicts Alzheimer's Years Before Symptoms, Brain Changes
- An Infectious Combo Triples Risk Of MS, Study Says
- Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
- Physician compensation up 3% in 2025, but not all specialties saw raises: Medscape
- Pfizer recruits former Angel Lucy Liu for latest mission against cancer
- Teva launches new online schizophrenia community project
- One man’s journey from gambling addiction to recovery and advocacy
- Medi-Cal Immigrant Enrollment Is Dropping. Researchers Point to Trump’s Policies.
- Rural Nebraska Dialysis Unit Closes Despite the State’s $219M in Rural Health Funding
- Ionis exec shares method to the Madness after 2026 Drug Name Tournament win
- Abridge expands clinical decision support solution with UpToDate partnership, new NEJM, JAMA content tie-ups
- Travere maps course for Filspari's $3B US opportunity after landmark rare disease nod
- Hospitals with more disadvantaged patients fall short on price transparency, study finds
- FDA tells Eli Lilly to round up more safety info on key obesity launch Foundayo
- Meat Consumption Rises as Protein Trend Grows, Experts Warn
- Bill would force payers to apply DTC drug purchases to patient deductibles
- Nuts.com Recalls 10,000+ Pounds of Candy Over Allergy Risk
- Listen to the Latest ‘KFF Health News Minute’
- Estados cambian leyes para evitar que hijos de inmigrantes detenidos entren al sistema de cuidado temporal
- Keebler Health secures $16M in series A funding for AI-powered risk adjustment platform
- Sam’s Club Recalls Children’s Pajamas Due to Fire Hazard
- Small Talk? It May Be Better Than You Think
- J&J, chasing $100B year, sports immunology ‘dual powerhouse’ of Tremfya and new launch Icotyde
- Long-Term Opioid Prescriptions Fall By About A Quarter
- Gut Bacteria Might Drive Rare Food Allergy in Children, Study Finds
- Stents Can Ease Long-Term Symptoms Of Deep Vein Thrombosis, Trial Shows
- Young Cancer Survivors Face Doubled Risk Of Subsequent New Cancer
- Does Your Child Have Nightmares? Here's One Solution
- Marriage's Hidden Benefit? A Lower Risk Of Cancer
- Novo taps OpenAI to deploy AI across R&D, manufacturing and corporate functions
- Pfizer rebuked by FDA for misleading Adcetris ads on Facebook
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results
- Freedom of Associations
- Interfacing with our Inner Demons: Comments on the Division of Trading and Markets' Statement on Certain User Interfaces
- Staff Statement Regarding Broker-Dealer Registration of Certain User Interfaces Utilized to Prepare Transactions in Crypto Asset Securities
- Statement Regarding Staff No-Action Letter to Bank of England
Think the author of this post has the entities suing the Federal government wrong. It is the Dayton Chamber of Commerce suing, with the backing of the U.S. Chamber of Commerce:
US Chamber of Commerce sues over government's drug pricing power
By Jonathan Stempel - June 9, 2023June 9 (Reuters) - The U.S. Chamber of Commerce on Friday sued the federal government, challenging a new law that for the first time gives Medicare the power to negotiate drug prices with pharmaceutical companies.
In a complaint filed in federal court in Dayton, Ohio, the chamber said the pricing program violated drugmakers' due process rights under the U.S. Constitution by giving the government "unfettered discretion" to dictate maximum prices.
It also said the program would impose exorbitant penalties on drugmakers that don't accept those prices, and amounted to an ultimatum: "agree to whatever price the government names, or we'll smash up your business."
The U.S. Department of Health and Human Services administers Medicare through its Centers for Medicare & Medicaid Services.
A spokeswoman said the agency will vigorously defend the program, which is already helping lower healthcare costs for older adults and people with disabilities. "The law is on our side," she added.
Friday's lawsuit by the chamber, one of the most powerful U.S. business groups, came three days after Merck & Co (MRK.N) filed a similar lawsuit in Washington, D.C.
Both lawsuits contended that price controls would force drugmakers to pull back on developing new drugs, causing long-term harm to Americans and their health.
Other drugmakers have also objected to the pricing program, which is part of last year's Inflation Reduction Act. Pricing changes following negotiations on 10 costly drugs selected by CMS would take effect in 2026.
Americans pay more for prescription drugs than prices in any other country.
The Biden administration hopes to save $25 billion annually by 2031 by having Medicare, the government health plan for people 65 and over, negotiate prices.
White House spokeswoman Karine Jean-Pierre said on Tuesday the government was confident it would win the Merck case.
"There is nothing in the Constitution that prevents Medicare from negotiating lower drug prices," she said.
The chamber also warned that allowing the pricing program would set a bad precedent.
"After all, if the government can impose price controls in the pharmaceutical industry, why not elsewhere?" Chief Policy Officer Neil Bradley said in a statement.
The case is Dayton Area Chamber of Commerce et al v Becerra et al, U.S. District Court, Southern District of Ohio, No. 23-00156.
Now up to 4 Pharma/Chamber of Commerse lawsuits contesting Medicare drug price negotiation.
Pharmaceutical trade group sues US over Medicare drug price negotiation plans
NEW YORK, June 21 (Reuters) - The Pharmaceutical Research and Manufacturers of America (PhRMA), the leading industry lobby group, and two other organizations on Wednesday said they were suing the U.S. government to block enforcement of a program that gives Medicare the power to negotiate drug prices.
In a complaint filed in a federal court in Texas, PhRMA along with the National Infusion Center Association and the Global Colon Cancer Association, which counts PhRMA and some drug companies as members, said the drug price negotiation program was unconstitutional.
This marks the fourth lawsuit challenging the law, which is part of President Joe Biden’s signature Inflation Reduction Act (IRA), after separate legal challenges by Merck & Co (MRK.N), Bristol Myers Squibb (BMY.N), and the influential business group the U.S. Chamber of Commerce.
The pharmaceutical industry claims negotiating prices of its products with the government health plan for Americans age 65 and older will curtail profits and compel them to pull back on developing groundbreaking new treatments.
PhRMA represents many of the largest pharmaceutical companies in the world, including Merck and Bristol Myers.
Americans pay more for prescription medicines than any other country. The Biden administration's drug pricing reform aims to save $25 billion annually by 2031 through price negotiations for the drugs most costly to Medicare.
The latest lawsuit argues that the "unrestrained authority" given to the Department for Health and Human Services (HHS) by Congress conflicts with the United States' separation-of-power principle.
"Congress took a series of unconstitutional shortcuts, giving the executive branch the open ended task of replacing market based prices in Medicare with an entirely new set of prices at the (Medicare) agency's own choosing," PhRMA general counsel James Stansel said at a press conference.
The lawsuit also contends that the price negotiation program violates the U.S. Constitution's Eight Amendment, which protects against excessive fines, and Fifth Amendment by exempting key decisions from public input.
PhRMA and the other two groups are seeking an injunction against the price caps and a declaration that the IRA's price negotiation is unconstitutional.
The negotiations are scheduled to start in September after the agency that runs Medicare and Medicaid releases its list of 10 costly drugs initially selected for the process, with the agreed prices taking effect in 2026.
The suits challenging the plan have been filed in four different federal courts, with Merck's in Washington, D.C., the Chamber of Commerce in Ohio and Bristol Myers' in New Jersey.
In response to the previous lawsuits, the White House said there is nothing in the U.S. Constitution that prevents Medicare from negotiating lower drug prices.
A spokesperson for HHS on Wednesday said the law is on its side.
“As the (HHS) secretary has already made clear, we will vigorously defend the president’s drug price negotiation law, which is already helping to lower healthcare costs for seniors and people with disabilities."
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














